The efficacy influenced on the timing of anti-VEGF treatment in pro re nata regimen for recurrence of diabetic macular edema

The efficacy influenced on the timing of anti-VEGF treatment in pro re nata regimen for recurrence of diabetic macular edema - The timing of anti-VEGF treatment for DME

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000039134

Enrollment

Registered

2020-01-13

Start date

2020-01-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic macular edema

Interventions

waiting time is less than 1 week waiting time is more than 1 month

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes with DME who underwent intravitreal injection of anti-VEGF agent in 1+PRN regimen

Exclusion criteria

Exclusion criteria: (1) <20 years of age; 2) focal/grid photocoagulation or panretinal photocoagulation within the previous 6 months; (3) active intraocular inflammation or infection in either eye; (4) uncontrolled glaucoma in either eye; (5) a history of intravitreal injections of steroids during the observational periods; (6) a history of stroke; (7) a systolic blood pressure (BP) > 160 mm Hg, a diastolic BP > 100 mm Hg or untreated hypertension and (8) glycosylated hemoglobin (HbA1c) more than 10%.

Design outcomes

Primary

Measure	Time frame
central retinal thickness, visual acuity	—

Countries

Japan

Contacts

Public ContactYoshihiro Takamura

Faculty of Medical Sciences, University of Fukui Department of Ophthalmology

ytakamura@hotmail.com+81-776-61-8403

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026